Prognostic factors in stage III non-small cell lung cancer: A review of conventional, metabolic and new biological variables

Therapeutic Advances in Medical Oncology

Volumn 3, Issue 3, 2011, Pages 127-138

  Berghmans, Thierry ^a   Paesmans, Marianne ^a   Sculier, Jean Paul ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

non small cell lung carcinoma; performance status; prognosis; stage

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; FLUORODEOXYGLUCOSE F 18; VINBLASTINE;

APOPTOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE REGULATION; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SURGERY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

EID: 79960209587     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834011401951     Document Type: Review

References (81)

1. Ademuyiwa F.O. Johnson C.S. White A.S. Breen T.E. Harvey J. Neubauer M. et al (2007) Prognostic factors in stage III non-small-cell lung cancer. Clin Lung Cancer 8: 478–482.
2. Albain K.S. Swann R.S. Rusch V.W. Turrisi A.T. III Shepherd F.A. Smith C. et al (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374: 379–386.
3. Andre F. Grunenwald D. Pignon J.P. Dujon A. Pujol J.L. Brichon P.Y. et al (2000) Survival of patients with resected N 2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18: 2981–2989.
4. Barlesi F. Doddoli C. Torre J.P. Giudicelli R. Fuentes P. Thomas P. et al (2005) Comparative prognostic features of stage IIIAN 2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy. Eur J Cardiothorac Surg 28: 629–634.
5. Basaki K. Abe Y. Aoki M. Kondo H. Hatayama Y. Nakaji S. (2006) Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys 64: 449–454.
6. Berghmans T. Dusart M. Paesmans M. Hossein-Foucher C. Buvat I. Castaigne C. et al (2008 a) Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 3: 6–12.
7. Berghmans T. Mascaux C. Haller A. Meert A.P. van Houtte P. Sculier J.P. (2008 b) EGFR, TTF-1 and Mdm 2 expression in stage III non-small cell lung cancer: a positive association. Lung Cancer 62: 35–44.
8. Berghmans T. Mascaux C. Martin B. Ninane V. Sculier J.P. (2005 a) Prognostic role of p 53 in stage III non-small cell lung cancer. Anticancer Res 25: 2385–2389.
9. Berghmans T. Mascaux C. Martin B. Ninane V. Sculier J.P. (2006 a) Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer. Lung Cancer 52: 219–224.
10. Berghmans T. Meert A.P. Martin B. Ninane V. Sculier J.P. (2005 b) Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer. Eur Respir J 25: 329–335.
11. Berghmans T. Paesmans M. Mascaux C. Martin B. Meert A.P. Haller A. et al (2006 b) Thyroid transcription factor 1–a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol 17: 1673–1676.
12. Betticher D.C. Hsu Schmitz S.F. Totsch M. Hansen E. Joss C. von Briel C. et al (2006) Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN 2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 94: 1099–1106.
13. Boyle P. Ferlay J. (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481–488.
14. Broermann P. Junker K. Brandt B.H. Heinecke A. Freitag L. Klinke F. et al (2002) Trimodality treatment in Stage III nonsmall cell lung carcinoma: prognostic impact of K-ras mutations after neoadjuvant therapy. Cancer 94: 2055–2062.
15. Brooks K.R. To K. Joshi M.B. Conlon D.H. Herndon J.E. D'Amico T.A. et al (2003) Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg 76: 187–193.
16. Brundage M.D. Davies D. Mackillop W.J. (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122: 1037–1057.
17. Caglar H.B. Baldini E.H. Othus M. Rabin M.S. Bueno R. Sugarbaker D.J. et al (2009) Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer 115: 4156–4166.
18. Chang J.Y. Komaki R. Sasaki R. Liao Z. Stevens C.W. Lu C. et al (2005) High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res 11: 2894–2898.
19. Choi Y.S. Shim Y.M. Kim J. Kim K. (2002) Recurrence-free survival and prognostic factors in resected pN 2 non-small cell lung cancer. Eur J Cardiothorac Surg 22: 695–700.
20. Choma D. Daures J.P. Quantin X. Pujol J.L. (2001) Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data. Br J Cancer 85: 14–22.
21. Coen V. van Lancker M. de Neve W. Storme G. (1995) Prognostic factors in locoregional non-small cell lung cancer treated with radiotherapy. Am J Clin Oncol 18: 111–117.
22. Delmotte P. Martin B. Paesmans M. Berghmans T. Mascaux C. Meert A.P. et al (2002) VEGF et survie des patients avec cancer pulmonaire: une revue systématique de la littérature avec méta-analyse. Rev Mal Respir 19: 577–584.
23. Eschmann S.M. Friedel G. Paulsen F. Reimold M. Hehr T. Budach W. et al (2006) Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging 33: 263–269.
24. Fan J. Wang L. Jiang G.N. He W.X. Ding J.A. (2008) The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer 61: 91–96.
25. Firat S. Byhardt R.W. Gore E. (2002) Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 54: 357–364.
26. Furuse K. Fukuoka M. Kawahara M. Nishikawa H. Takada Y. Kudoh S. et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692–2699.
27. Garrido P. Gonzalez-Larriba J.L. Insa A. Provencio M. Torres A. Isla D. et al (2007) Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 25: 4736–4742.
28. Garrido P. Rosell R. Massuti B. Cardenal F. Alberola V. Domine M. et al (2009) Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy. Clin Lung Cancer 10: 180–186.
29. Goldstraw P. Crowley J. Chansky K. Giroux D.J. Groome P.A. Rami-Porta R. et al (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2: 706–714.
30. Graziano S.L. Tatum A. Herndon J.E. Box J. Memoli V. Green M.R. et al (2001) Use of neuroendocrine markers, p53, and HER 2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 33: 115–123.
31. Grossi F. Spizzo R. Bordo D. Cacitti V. Valent F. Rossetto C. et al (2010) Prognostic stratification of stage IIIA pN 2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014). J Thorac Oncol 5: 1354–1360.
32. Hoang J.K. Hoagland L.F. Coleman R.E. Coan A.D. Herndon J.E. Patz E.F. Jr (2008) Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 26: 1459–1464.
33. Huncharek M. Kupelnick B. Geschwind J.F. Caubet J.F. (2000) Prognostic significance of p 53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer Lett 153: 219–226.
34. Huncharek M. Muscat J. Geschwind J.F. (1999) K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 20: 1507–1510.
35. Hwang J.H. Lim S.C. Kim Y.C. Park K.O. Ahn S.J. Chung W.K. (2001) Apoptosis and bcl-2 expression as predictors of survival in radiation-treated non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 50: 13–18.
36. Jeremic B. Shibamoto Y. (1995) Pre-treatment prognostic factors in patients with stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy. Lung Cancer 13: 21–30.
37. Kameyama K. Huang C.L. Liu D. Okamoto T. Hayashi E. Yamamoto Y. et al (2002) Problems related to TNM staging: patients with stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 124: 503–510.
38. Kim K.J. Ahn Y.C. Lim do H. Han J. Park K. Park J.O. et al (2007) Analyses on prognostic factors following tri-modality therapy for stage IIIa non-small cell lung cancer. Lung Cancer 55: 329–336.
39. Kim S.H. Cho B.C. Choi H.J. Chung K.Y. Kim D.J. Park M.S. et al (2008) The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC. Lung Cancer 60: 393–400.
40. Kreuter M. Kropff M. Fischaleck A. Junker K. Gerss J. Heinecke A. et al (2009) Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment. Eur Respir J 33: 1383–1388.
41. Langendijk H. Aaronson N.K. de Jong J.M. ten Velde G.P. Muller M.J. Wouters M. (2000 a) The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 55: 19–25.
42. Langendijk H. Thunnissen E. Arends J.W. de Jong J. ten Velde G.P. Lamers R. et al (2000 b) Cell proliferation and apoptosis in stage III inoperable non-small cell lung carcinoma treated by radiotherapy. Radiother Oncol 56: 197–207.
43. Lee J.G. Lee C.Y. Park I.K. Kim D.J. Cho S.H. Kim K.D. et al (2008) The prognostic significance of multiple station N 2 in patients with surgically resected stage IIIA N 2 non-small cell lung cancer. J Korean Med Sci 23: 604–608.
44. Lorent N. de Leyn P.R. Lievens Y. Verbeken E. Nackaerts K. Dooms C. et al (2004) Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 15: 1645–1653.
45. Martin B. Paesmans M. Berghmans T. Branle F. Ghisdal L. Mascaux C. et al (2003) Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 89: 55–64.
46. Martin B. Paesmans M. Mascaux C. Berghmans T. Lothaire P. Meert A.P. et al (2004) Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 91: 2018–2025.
47. Martins S.J. Pereira J.R. (1999) Clinical factors and prognosis in non-small cell lung cancer. Am J Clin Oncol 22: 453–457.
48. Mascaux C. Iannino N. Martin B. Paesmans M. Berghmans T. Dusart M. et al (2005) The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92: 131–139.
49. Mascaux C. Martin B. Paesmans M. Berghmans T. Dusart M. Haller A. et al (2006) Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer 95: 139–145.
50. Meert A.P. Martin B. Delmotte P. Berghmans T. Lafitte J.J. Mascaux C. et al (2002 a) The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 20: 975–981.
51. Meert A.P. Martin B. Paesmans M. Berghmans T. Mascaux C. Verdebout J.M. et al (2003) The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer 89: 959–965.
52. Meert A.P. Paesmans M. Martin B. Delmotte P. Berghmans T. Verdebout J.M. et al (2002 b) The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 87: 694–701.
53. Mitsudomi T. Hamajima N. Ogawa M. Takahashi T. (2000) Prognostic significance of p 53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6: 4055–4063.
54. Morero J.L. Poleri C. Martin C. van Kooten M. Chacon R. Rosenberg M. (2007) Influence of apoptosis and cell cycle regulator proteins on chemotherapy response and survival in stage IIIA / IIIB NSCLC patients. J Thorac Oncol 2: 293–298.
55. Mountain C.F. (1986) A new international staging system for lung cancer. Chest 89: 225S–233S.
56. Mountain C.F. (1997) Revisions in the International System for Staging Lung Cancer. Chest 111: 1710–1717.
57. Nakamura H. Kawasaki N. Taguchi M. Kabasawa K. (2005) Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. Cancer 103: 1865–1873.
58. Nakamura H. Kawasaki N. Taguchi M. Kabasawa K. (2006) Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 61: 140–145.
59. Nakamura T. Fuwa N. Kodaira T. Tachibana H. Tomoda T. Nakahara R. et al (2008) Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy. Lung 186: 91–96.
60. Niizeki H. Morikawa T. Okushiba S. Kondo S. Katoh H. (2004) Survival and prognostic factors in resected cN2-pN0 non-small cell lung cancer. Ann Thorac Cardiovasc Surg 10: 9–13.
61. Osaki T. Sugio K. Hanagiri T. Takenoyama M. Yamashita T. Sugaya M. et al (2003) Survival and prognostic factors of surgically resected T 4 non-small cell lung cancer. Ann Thorac Surg 75: 1745–1751.
62. Paesmans M. Berghmans T. Dusart M. Garcia C. Hossein-Foucher C. Lafitte J.J. et al (2010) Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 5: 612–619.
63. Riquet M. Bagan P. Le Pimpec Barthes F. Banu E. Scotte F. Foucault C. et al (2007) Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N 2 metastases. Ann Thorac Surg 84: 1818–1824.
64. Sculier J.P. Chansky K. Crowley J.J. van Meerbeeck J. Goldstraw P. (2008) The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 3: 457–466.
65. Sculier J.P. Lafitte J.J. Berghmans T. van Houtte P. Lecomte J. Thiriaux J. et al (2004) A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann Oncol 15: 399–409.
66. Sculier J.P. Paesmans M. Lafitte J.J. Baumohl J. Thiriaux J. van Cutsem O. et al (1999 a) A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party. Ann Oncol 10: 295–303.
67. Sculier J.P. Paesmans M. Lafitte J.J. Baumohl J. Thiriaux J. van Cutsem O. et al (1999 b) Prognostic factors analysis for response to chemotherapy and survival in a prospective cohort of patients with unresectable locoregional non small cell lung cancer initially treated by induction chemotherapy. Rev Oncologia 1: 92–100.
68. Socinski M.A. Zhang C. Herndon J.E. Dillman R.O. Clamon G. Vokes E. et al (2004) Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 15: 1033–1041.
69. Spierings D.C. de Vries E.G. Timens W. Groen H.J. Boezen H.M. de Jong S. (2003) Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 9: 3397–3405.
70. Steels E. Paesmans M. Berghmans T. Branle F. Lemaitre F. Mascaux C. et al (2001) Role of p 53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18: 705–719.
71. Stinchcombe T.E. Morris D.E. Moore D.T. Bechtel J.H. Halle J.S. Mears A. et al (2006) Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy. Lung Cancer 52: 67–74.
72. Suzuki K. Nagai K. Yoshida J. Nishimura M. Takahashi K. Nishiwaki Y. (1999 a) The prognosis of surgically resected N 2 non-small cell lung cancer: the importance of clinical N status. J Thorac Cardiovasc Surg 118: 145–153.
73. Suzuki K. Nagai K. Yoshida J. Nishimura M. Takahashi K. Yokose T. et al (1999 b) Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer 86: 1976–1984.
74. Tanaka F. Yanagihara K. Otake Y. Kawano Y. Miyahara R. Takenaka K. et al (2004) Prognostic factors in resected pathologic (p-) stage IIIA-N2, non-small-cell lung cancer. Ann Surg Oncol 11: 612–618.
75. Tomita M. Matsuzaki Y. Shimizu T. Hara M. Ayabe T. Onitsuka T. (2006) Preoperative prognostic factors for pN 2 non-small cell lung cancer. Ann Thorac Cardiovasc Surg 12: 15–20.
76. Trivella M. Pezzella F. Pastorino U. Harris A.L. Altman D.G. (2007) Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol 8: 488–499.
77. Uramoto H. Osaki T. Inoue M. Taga S. Takenoyama M. Hanagiri T. et al (1999) Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer 35: 1462–1465.
78. van Meerbeeck J.P. Kramer G.W. van Schil P.E. Legrand C. Smit E.F. Schramel F. et al (2007) Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99: 442–450.
79. Vansteenkiste J.F. de Leyn P.R. Deneffe G.J. Stalpaert G. Nackaerts K.L. Lerut T.E. et al (1997) Survival and prognostic factors in resected N 2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg 63: 1441–1450.
80. Vokes E.E. Herndon J.E. Kelley M.J. Cicchetti M.G. Ramnath N. Neill H. et al (2007) Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25: 1698–1704.
81. Zhan P. Wang J. Lv X.J. Wang Q. Qiu L.X. Lin X.Q. et al (2009) Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 4: 1094–1103.